Gaussian

Equity Research Monitor

EMEA Healthcare

The latest in enterprise and strategic research are at your fingertips below, summarized in Gaussian's research monitor.

Lokman Hekim - Potential New Acquisition to add 200 bed capacity

Lokman Hekim - Potential New Acquisition to add 200 bed capacity

Lokman have had a busy quarter with investor events. Expect more in 2H18. Both trading and investments appear on track to meet guidance.

Read More

Lokman Hekim 2020 results and outlook

Lokman Hekim 2020 results and outlook

Lokman have had a busy quarter with investor events. Expect more in 2H18. Both trading and investments appear on track to meet guidance.

Read More

Lokman Hekim HYSET - Online exchange place for medical services

Lokman Hekim HYSET - Online exchange place for medical services

HYSET is a marketplace for medical services. The platform offers patients seeking care access to a network of healthcare providers. The business is headquartered in Ankara.

Read More

HYSET by Lokman Hekim - the 21st Century Care with Price Transparency on Offer

HYSET by Lokman Hekim - the 21st Century Care with Price Transparency on Offer

Her Yerde Saglik ve Elektronik Ticaret A.S. (HYSET), a wholly-owned subsidiary of Lokman Hekim, operates a marketplace for healthcare services where patients match their needs with products and packages the network hospitals have on offer.

Read More

GEM Healthcare - HYSET, Lokman Hekim's Venture in MedTech

GEM Healthcare - HYSET, Lokman Hekim's Venture in MedTech

Lokman has invested in a medical technology company to establish an exclusive online marketplace for healthcare services. Her Yerde Saglik ve Elektronik Ticaret A.S. (HYSET) is a wholly-owned subsidiary of Lokman. The medical marketplace helps patients match their needs and requirements with services available in the network.

Read More

GEM Healthcare - Lokman Hekim on track to meet guidance

GEM Healthcare - Lokman Hekim on track to meet guidance

Lokman have had a busy quarter with investor events. Expect more in 2H18. Both trading and investments appear on track to meet guidance.

Read More